*[Enwl-eng] SARS-CoV-2: The Battle against COVID-19 has just Begun

[ENWL]

SARS-CoV-2: The Battle against COVID-19 has just Begun



                  Products are for research use only and are not intended 
for human use. We do not sell to patients.
                  If you no longer wish to receive these emails you may 
unsubscribe at any time.

                  SARS-CoV-2 — The Battle against Coronavirus has just Begun

                  • SARS-CoV-2 showed highly pathogenic, caused severe or 
even life-threatening diseases, and still transmitted from person-to-person.
                  • The World Health Organization declared a global pandemic 
as the coronavirus (SARS-CoV-2) rapidly spreads across the world.
                  • Until now, no drugs or biologics have been proven to be 
effective for the prevention or treatment of COVID-19.
                  SARS-CoV-2 — Promising Antiviral Agents

                        Favipiravir
                        (T-705)
                       Selectively and potently inhibits the RNA-dependent 
RNA polymerase(RdRp) of RNA viruses. Shows good clinical efficacy in 
treating COVID-19.

                        Remdesivir
                        (GS-5734)
                       A nucleotide analog inhibitor of RdRp. Against 
SARS-CoV, MERS-CoV and Ebola virus. Effectively inhibits SARS-CoV-2 in 
vitro. Enters phase III trial.

                        Chloroquine
                        Phosphate
                       An antimalarial agent. Inhibits autophagy and 
toll-like receptors (TLRs). Effectively inhibits SARS-CoV-2 in vitro. FDA 
approved.

                        Hydroxychloro-
                        quine sulfate
                       An antimalarial and anti-inflammatory agent. Inhibits 
TLR7/9 signaling. Efficiently inhibits SARS-CoV-2 infection in vitro. FDA 
approved.


                  MedChemExpress Anti-COVID-19 Compound Library based on 
Relevant Proteins:
                  We conduct Virtual Screening of approved compound library 
and clinical compound library based on 3CLpro (PDB ID: 6LU7), RdRp, Spike 
Glycoprotein (PDB ID: 6VSB), nsp15 (PDB ID: 6VWW), PLpro and ACE2 Structure.
                  Partial Screening Library Data:
                        SARS-CoV-2
                       Compounds
                       Information

                        3CLpro
                       Saquinavir
                       An HIV Protease inhibitor. FDA approved.

                        Carfilzomib
                       An irreversible proteasome inhibitor. FDA approved.

                        Nelfinavir
                       An orally bioavailable HIV-1 protease inhibitor (Ki=2 
nM) and antiviral agent. FDA approved.

                        S Protein & ACE2
                       Bimosiamose
                       A nonoligosaccharide pan-selectin inhibitor and has 
anti-
                        inflammatory effects. Phase 2.

                        RdRp
                       Zanamivir
                       An influenza viral neuraminidase inhibitor. FDA 
approved.

                        nsp15
                       Ribavirin
                       An antiviral agent against a broad spectrum of 
viruses including HCV, HIV, and RSV. FDA approved.

                        PLpro
                       Epetraborole
                        hydrochloride
                       A leucyl-tRNA synthetase (LeuRS) inhibitor. Intended 
for the infections caused by Gram-negative bacteria. Phase 2.


                        MCE USA Tel: 609-228-6898  E-mail: 
sales at MedChemExpress.com
                        Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, 
NJ 08852, USA
                        MCE Europe Tel: +4686500910  E-mail: 
eu.sales at MedChemExpress.com
                        Address: Bergkällavägen 37C 192 79 Sollentuna SWEDEN


                  We respect your privacy and do not share or sell your 
information to third parties.



      View this email in your browser
      You are receiving this email because of your relationship with 
medchemexpress. Please reconfirm your interest in receiving emails from us.

            Address: 9 Deer Park Drive, Suite K2,, Monmouth Junction, New 
Jersey, 08852

            | Manage Subscription | Forward Email | Report Abuse



      From: MedChemExpress LLC
      Sent: Wednesday, March 25, 2020 6:30 PM
      Subject: SARS-CoV-2: The Battle against COVID-19 has just Begun

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.enwl.net.ru/pipermail/enwl-eng/attachments/20200331/915d1f22/attachment-0001.html>